The Cunningham Panel is a series of tests which assist physicians in diagnosing treatable autoimmune neurologic conditions, such as PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Strep infections) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Patients with these syndromes are often misdiagnosed as having a psychiatric illness and prescribed psychotropic medications, when, in fact, their symptoms are due to an autoimmune dysfunction, which may require a different treatment approach. The Panel consists of five assays and is the first and only test of kinds in the world. It is offered exclusively through Moleculera Labs, Inc. Testing for patients living outside the United States is also available.